- Home
- Publications
- Publication Search
- Publication Details
Title
Vaccine Strategies in Gliomas
Authors
Keywords
Glioma, Immunotherapy, Neoepitope, Vaccine, IDH1, Personalized
Journal
Current Treatment Options in Neurology
Volume 20, Issue 5, Pages -
Publisher
Springer Nature
Online
2018-03-28
DOI
10.1007/s11940-018-0498-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy
- (2017) Zinal S. Chheda et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Vaccine-based immunotherapeutic approaches to gliomas and beyond
- (2017) Michael Weller et al. Nature Reviews Neurology
- Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
- (2017) Lidia M. Yshii et al. Nature Reviews Neurology
- EGFRvIII vaccine in glioblastoma—InACT-IVe or not ReACTive enough?
- (2017) Michael Platten NEURO-ONCOLOGY
- K27M-mutant histone-3 as a novel target for glioma immunotherapy
- (2017) Katharina Ochs et al. OncoImmunology
- Concepts in glioma immunotherapy
- (2016) Michael Platten et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
- (2016) R. Rampling et al. CLINICAL CANCER RESEARCH
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Neurological sequelae of cancer immunotherapies and targeted therapies
- (2016) Wolfgang Wick et al. LANCET ONCOLOGY
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
- (2016) Lena M. Kranz et al. NATURE
- Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
- (2016) T. M. Johanns et al. Cancer Discovery
- Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
- (2016) Valérie Dutoit et al. Frontiers in Oncology
- Cancer immunotherapy: exploiting neoepitopes
- (2015) Michael Platten et al. CELL RESEARCH
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer
- (2015) Sebastian Kreiter et al. NATURE
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
- (2015) J. Schuster et al. NEURO-ONCOLOGY
- Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas
- (2015) Martin J. van den Bent et al. NEURO-ONCOLOGY
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial
- (2015) Friedrich H Schmitz-Winnenthal et al. OncoImmunology
- Mutant IDH1: An immunotherapeutic target in tumors
- (2015) Theresa Schumacher et al. OncoImmunology
- Microenvironmental Clues for Glioma Immunotherapy
- (2014) Michael Platten et al. Current Neurology and Neuroscience Reports
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- Epidermal growth factor receptor and variant III targeted immunotherapy
- (2014) K. L. Congdon et al. NEURO-ONCOLOGY
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial
- (2013) Orin Bloch et al. NEURO-ONCOLOGY
- Protein kinase Cβ as a therapeutic target stabilizing blood–brain barrier disruption in experimental autoimmune encephalomyelitis
- (2013) Tobias V. Lanz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
- (2012) Valérie Dutoit et al. BRAIN
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
- (2012) Surasak Phuphanich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
- (2010) John H. Sampson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen–A24 With Recurrent or Progressive Glioblastoma Multiforme
- (2010) Mizuhiko Terasaki et al. JOURNAL OF CLINICAL ONCOLOGY
- An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
- (2009) J. H. Sampson et al. MOLECULAR CANCER THERAPEUTICS
- Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
- (2008) Shuichi Izumoto et al. JOURNAL OF NEUROSURGERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation